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Abstract 
At its re-birth 30 years ago, the neurodevelopment hypothesis of 
schizophrenia focussed on aberrant genes and early neural hazards, but 
then it grew to include ideas concerning aberrant synaptic pruning in 
adolescence. The hypothesis had its own stormy development and it 
endured some difficult teenage years when a resurgence of interest in 
neurodegeneration threatened its survival. In early adult life, it over-
reached itself with some reductionists claiming that schizophrenia was 
simply a neurodevelopmental disease. However, by age 30, the 
hypothesis has matured sufficiently to incorporated childhood and adult 
adversity, urban living and migration, as well as heavy cannabis use, as 
important risk factors. Thus, it morphed into the developmental risk 
factor model of psychosis and integrated new evidence concerning 
dysregulated striatal dopamine as the final step on the pathway linking 
risk factors to psychotic symptoms.  
Key words: neurodevelopment; sociodevelopment; dopamine; risk 
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The Origins of the Neurodevelopmental Hypothesis 
  
A neurodevelopmental approach to psychosis was first postulated by 
the Scottish psychiatrist Thomas Clouston in 1891.1 However, his ideas 
were soon displaced by Kraepelin’s conceptualization of dementia 
praecox as an adult onset neurodegenerative disorder,2 a view which 
held sway for nearly a century. Indeed, in the late 1970s, when 
Johnstone et al3,4 demonstrated that people with chronic schizophrenia 
had lateral ventricular enlargement and cognitive deficits, they 
interpreted their findings as confirming “the dementia of dementia 
praecox.”  
However, in 1982, we reported that monozygotic (MZ) twins with 
schizophrenia had larger cerebral ventricles than their MZ but well 
cotwins. This implied that the larger ventricles were environmental in 
origin, and we noted that the affected twins had been exposed to more 
severe perinatal hazards.5 In a series of articles, we con- firmed the role 
of pre- and perinatal complications in a larger number of discordant as 
opposed to concordant MZ twins6 as well as in singleton patients with 
schizophrenia7; the latter had, of course, been previously reported, 
particularly from Scandinavia.8 However, now we could link the 
neuroimaging findings with the emerging paediatric literature showing 
that periventricular bleeding in the brains of neonates exposed to 
prematurity and/or hypoxia often resulted in ventricular enlargement.7,9 
We also pointed to the evidence that people with schizophrenia were 
more likely to have been born in the late winter and spring, possibly 
due to prenatal exposure to maternal infections.9  
These facts, and what we termed the “curious epiphemenomena” of 
schizophrenia10 such as childhood neuromotor and minor physical 
anomalies, could not readily be accommodated within the Kraepelinian 
degenerative model. As Jablensky et al11 have demonstrated elsewhere 
in this issue, interest in a developmental approach had already begun to 
revive, and so the neurodevelopmental hypothesis was explicitly 
proposed by Weinberger12 in the United States and by ourselves8 in the 
United Kingdom. Subsequent studies confirmed that low birth- weight, 
hypoxia, and other obstetric hazards7,13 are linked to increased risk of 
schizophrenia, as are prenatal exposure to viral infection14 and 
nutritional deficiencies.15 Some studies reported that obstetric events 
were associated with brain structural abnormalities in schizophrenic 
patients,16 but others did not. This latter was surprising since the 
sequelae of hypoxia and other fetal hazards can readily be seen in the 
brains of nonpsychotic adults who had been born very preterm.17 In 
retrospect, it seems that the developmental changes are masked in 
people with schizophrenia by the effects of antipsychotics and lifestyle 
factors such as illicit drug abuse on the brain.18 As exception is 
abnormal gyrification which remains a marker of aberrant foetal 
development in schizophrenia and is associated with lack of treatment 
response.19  
Evolution has, of course, provided the brain with resilience to insult. 
For example, Marin20 points out that during childbirth, a reduction in 
the intracellular chloride concentration of neurons leads to an 
excitatory-to-inhibitory switch of γ-amino butyric acid actions which 
increases the resistance of neurons to hypoxic damage during delivery. 
Thus, an important question is whether part of the genetic 
predisposition to schizophrenia may operate by impairing the resilience 
of the fetal and neo- natal brain.21 Furthermore, early insults to the brain 
can result in the developing neuronal circuits reorganizing well into 
adulthood. Thus, the pathological neural connectivity in some adults 
with schizophrenia may be the result of multiple compensatory 
mechanisms operating throughout development. Certainly, such is the 
case for adults who were born preterm.17,22  
An important component of early formulations of the 
neurodevelopmental hypotheses was neuropathological report of 
hippocampal aberrations that could have only arisen through abnormal 
early neuronal migration.23 Unfortunately, these reports were never 
replicated and gradually faded from view. However, support for the 
neurodevelopmental hypothesis came from rodent models such as the 
neonatal ventral hippocampal lesion model24 and prenatal exposure to 
methylazoxymethanol acetate (MAM).25 The adult offspring of MAM-
treated rats displays many characteristics found in schizophrenia, 
including neuroanatomic changes (thinning of limbic cortices with an 
increase in cell packing density, loss of parvalbumin interneurons), 
behavioral deficits (prepulse inhibition, latent inhibition), and increased 
locomotion in response to amphetamine.25 Such animal models are 
described in detail by Kanyuch and Anderson elsewhere in this issue26  
The neurodevelopmental hypothesis marched on, fuelled by cohort 
studies which examined characteristics of preschizophrenic children. 
Thus, an initial analysis of the British 1946 Birth Cohort by Jones et 
al27 showed subtle neuromotor and speech delays, solitariness, and 
lower educational test scores by age 8. Then, using data from the 
Dunedin Longitudinal Study, our group reported that minor psychotic 
symptoms in early adolescence predicted increased risk of adult 
psychosis28 and showed how children destined to develop 
schizophrenia-like psychoses gradually fell increasingly behind normal 
children in cognitive capacities as they aged from infancy to 
adolescence29  
Part of the success of the neurodevelopmental hypothesis can be 
attributed to its elasticity. For example, early papers postulated that the 
effects of genetic predisposition30 and early adverse events7 would only 
manifest as psychosis in early adulthood when normative maturational 
changes unmasked the earlier insult. However, in 1994, Keshavan31 
relaunched the hypothesis originally proposed by Feinberg32 that the 
critical process might be aberrant synaptic pruning during adolescence. 
Support for this latter view has recently come from Sekar et al33 who 
claim that variation in compliment C4 genes may induce excessive 
synaptic pruning and from evidence that cortical volume loss appears to 
occur as psychosis onsets in adolescence and early adult life.34  
The Model Expands to Include Social and Drug Exposures  
Thus, neurodevelopmental models began to allow for disruptions to 
normal neural development throughout fetal life, childhood, and 
adolescence. This revision opened the door for consideration of the 
influence of other environmental exposures. A systematic review by 
McGrath et al35 convinced most researchers that there was consid- 
erable variation in the incidence of schizophrenia across populations. 
This had important aetiological implications—findings of variation in 
incidence were used to argue for more environmental and contextual 
influences on schizophrenia risk. Urban birth and upbringing, and 
indeed degree of urbanicity, were found to be associated with later risk 
of schizophrenia,36 and so, risk for schizophrenia was connected to area-
level, rather than to purely individual-level, variables.37 Of course, 
urbanicity must be a proxy for some other causal factor—crime, social 
fragmentation, and isolation have all been proposed.37,38  
Schizophrenia incidence was found to be increased in most migrant 
populations but especially in black people who had migrated into 
predominantly white European countries39, interestingly, living in areas 
where there is a substantial population of similar immigrants 
ameliorates the risk.40 A range of adversities in childhood such as loss 
of a parent, maltreatment, physical and sexual abuse, and bullying were 
also associated with increased risk,38 as were more proximal adverse life 
events.41 Now real-time sampling techniques have shown that patients 
with schizophrenia have greater sensitivity to everyday hassles than do 
controls and have linked even mild stress to increases in psychotic 
symptoms.42 Such findings extended the neurodevelopmental model and 
led to the proposal of a parallel sociodevelopmental model.43  
Increasing attention was also paid to drug-induced psychosis44 and in 
particular to the role of cannabis. In spite of residual scepticism,45 now 
the consensus is that heavy use of cannabis, especially of high-potency 
and synthetic forms, has a consistent, dose-related, effect in increasing 
risk of both psychotic symptoms and schizophrenia-like psychoses.46,47  
All Roads Lead to Dopamine  
Interest turned mechanisms underlying the onset of psychosis, and in 
particular the role of dopamine as the final common pathway 
underlying schizophrenia,48 and more recently, manic psychosis.49 
Increased dopamine synthesis capacity in the associative striatum is 
characteristic of people with psychotic disorders: furthermore, it is 
already detectable at the onset of prodromal symptoms and increases 
with proximity to transition into frank psychosis.50,51  
In rodents, acute stressors result in increased synthesis and release of 
striatal dopamine as dose isolation rearing as well as exposure to 
inflammatory challenges in utero.51 Similarly, position in the social 
hierarchy affects the dopamine system in monkeys.51  
As Kanyuch and Anderson point out elsewhere in this issue,26 early 
developmental disruption makes the dopamine system hyper-
responsiveness to stress, particularly during the rodent equivalence of 
adolescence.52 Emerging evidence shows similar effects in humans. For 
example, young adults who were exposed to childhood abuse or who 
are migrants show increased striatal dopamine synthesis capacity and 
increased dopamine release to experimentally induced psychosocial 
stress.53,54  
In general, risk factors for psychosis seem to be associated with 
increased striatal dopamine. However, two exceptions have been noted 
so far. Thus, our follow-up into adult life of infants who were born very 
preterm with perinatal brain injury show reduced dopamine synthesis 
capacity compared to those born very preterm without perinatal brain 
injury and controls born at full term; hippocampal volume was 
positively correlated with striatal dopamine synthesis capacity but was 
reduced in the peri- natal brain injury group.55 Similarly, chronic 
cannabis users, like other drug abusers, have low striatal dopamine, 
leading to the idea that in such individuals the locus of susceptibility 
may not be presynaptic but rather due to postsynaptic supersensitivity.56  
Genetics  
In contrast to 1987, we now know that schizophrenia risk is largely 
mediated by numerous common genetic variants each of tiny effect,57 
with a small proportion resulting from copy number variants with 
larger effect size. Some of these latter are shared with autism and 
learning disability, suggesting to Owen et al58 that there exists a 
neurodevelopmental continuum of genetic risk.  
It is now possible to derive a polygenic risk score for schizophrenia 
(PRS-SCZ) which reflects polygenic loading for the illness.57 The PRS-
SCZ accounts for about 9% of variance in caseness in studies of 
psychotic patients and controls.59 Interestingly, it has been associated 
with neurodevelopmental problems and/or negative symptoms in 
several studies of non-ill children,60 adolescents,61 and adults.62 In the 
huge UK Biobank sample, the PRS- SCZ predicts lower performance 
on a variety of cognitive tests.63 Schizophrenia patients with intellectual 
disability are particularly likely to show enrichment of rare damaging 
variants in developmental disorder genes, but a weaker but significant 
enrichment exists through- out the larger schizophrenia population.64 
Thus, many of the genetic variants associated with schizophrenia 
impact on brain development and in particular in cognitive 
development,65 thus confirming an early article27 entitled “The Genetics 
of Schizophrenia is the Genetics of Neurodevelopment.”  
Genome-Wide Association studies have not implicated genes directly 
involved in dopamine synthesis or release but instead point to upstream 
and downstream pathways linked to dopamine. Thus, a number of 
schizophrenia risk genes converge on glutamatergic systems which, of 
course, influence dopamine synthesis and release66 In addition, other 
risk genes affect dopamine receptors (eg, DRD2) and postsynaptic 
signal transduction pathways (AKT1 and 3) and thus modulate 
postsynaptic dopaminergic neurotransmission; DRD2 and AKT1 
appear to influence vulnerability to cannabis-associated psychosis.67 
Thus, risk genes for schizophrenia may play two disruptive roles: those 
influencing upstream factors render the midbrain dopamine neurons 
more vulnerable to dysregulation by the sociodevelopmental risk 
factors discussed earlier, while those influencing downstream factors 
amplify the effects of dysregulation.66  
The Developmental Risk Factor Model  
By the early years of the 21st century, the neurodevelopmental 
hypothesis was widely accepted. However, two threats to its viability 
appeared. First, interest in neurodegeneration began to revive following 
the demonstration that over the course of schizophrenia, the brain 
changes appeared to worsen68,69 Some researchers returned to neo-
Kraepelinian notions of progressive brain changes due to some intrinsic 
schizophrenic process.68,69 However, it was subsequently shown that the 
changes were due to a combination of the effects of antipsychotics, 
illicit drug use, and the unhealthy life- style of people with 
schizophrenia.17,70  
At the other extreme, another threat to the plausibility of the hypothesis 
arose from the uncritical adoption of the reductionist view that 
schizophrenia is simply a neurodevelopmental disorder.71 It is obvious 
that this is not so, at least not in the way that autism or learning dis- 
ability are neurodevelopmental disorders; rather neurodevelopmental 
risk factors interact with adverse social and drug risk factors, most of 
which act during development. Thus, deficits in neuro- and social- 
cognition, secondary to subtle abnormalities in neural networks, set 
some children on a trajectory of increasing scholastic difficulties, 
asociality, and isolation, features which are often rebadged in later life 
as primary negative symptoms. A cascade of increasing deviance 
occurs, and finally drug abuse, or exposure to victimisation or other 
adverse life events results in dysregulated dopamine release, leading to 
the aberrant assignment of salience to experiences and perceptions. 
Exposure to repeated social adversity may also bias the cognitive 
schema that the child uses, to interpret these excessively salient 
experiences in a paranoid manner.72 A vicious cycle can then be 
established: stress increases dopamine dysregulation, leading to more 
stress as consequence of the emerging psychotic experiences, and so 
further dopamine release, which eventually hardwires the psychotic 
interpretation.51  
Thus, the neurodevelopmental hypothesis has gradually morphed into 
the Developmental Risk Factor Model,51,66,73 an integrative framework 
with some similarities to Developmental Interactive Model outlined by 
Carpenter in Straus elsewhere in this issue.74 Such a model has to take 
into account evidence which has become available and indicates that 
schizophrenia is not a discrete disease entity but rather the severe end 
of a broader multidimensional psychosis spectrum.75 Numerous studies 
indicate that there exists a continuum of subclinical psychotic 
symptoms, often associated with subtle cognitive deficits,76 extending 
into the general population and that the same factors that influence risk 
of schizophrenia also influence the prevalence of minor psychotic 
symptoms in the general population.75–77  
Thus, liability to psychosis is distributed in the same way as liability to 
hypertension or obesity. If an individual’s blood pressure is persistently 
above a certain arbitrary level (90 mmHg in many countries), they are 
considered hypertensive; if the hypertension is not readily responsive to 
treatment, they may be further diagnosed as having severe or malignant 
hypertension. Similarly, if psychotic symptoms go beyond a certain 
threshold then a diagnosis of clinical psychotic disorder is appropriate, 
and if this persists and is associated with cognitive impairment of 
developmental origin, then a diagnosis of schizophrenia is made.  
Can we intervene usefully at some point in the develop- mental cascade 
toward illness? For a while it was thought that prodromal or “at-risk” 
clinics could play an important role in preventing psychosis. However, 
even in those areas with well organized outreach services, only a small 
proportion of those who develop a first episode of psychosis comes via 
such clinics; only 4% in South London.78 Consequently, if we wish to 
prevent a significant proportion of cases of psychosis, we must 
intervene at an earlier point.79  
Initially, it seemed possible that the occurrence of minor psychotic 
symptoms in early adolescence might specifically predict later 
psychosis.22 However, we now know that such minor symptoms 
indicate increased risk not only of later psychosis but also depression, 
suicidal ideas, and anxiety.80 Furthermore, they do not have sufficient 
predictive power to be useful. One possibility worth pursuing is to 
target those who carry several markers of deviance. Thus, Laurens et 
al,81 who examined children aged 9–12, suggested using a trilogy of 
antecedent markers (speech or motor delays; minor psychotic 
symptoms; and social, behavioural, or emotional problems) to identify 
those at sufficient risk to merit intervention. The Gur group82 has shown 
that youth with minor psychotic symptoms show cognitive deficits, 
reduced executive activation, exaggerated amygdala threat 
responsivity, and functional network dysconnectivity. Perhaps, an 
algorhithm using some combination of these markers may eventually 
be found to have predictive value in the clinic.  
There may also be a minority of cases which result from a specific 
remediable cause.23,26 The Velocadiofacial Syndrome results from a 
deletion at 22q11.2, is associated with cognitive difficulties, and up to 
one-third are reported to develop psychosis. A mouse model with a 
homologous deletion shows deficits in working-memory and impaired 
functional connectivity, accompanied by dysregulated Gsk3β signaling, 
which is part of the same pathway as AKT mentioned earlier.67 
Importantly, these mice can be rescued by Gsk3 antagonists,83 holding 
out the hope that eventually specific interventions early in life may 
prevent some uncommon causes of schizophrenia.  
However, such an approach is unlikely to impact on the majority of 
cases. Here, the knowledge that schizophrenia is the extreme of a 
continuum of psychosis has important implications. Preventive 
approaches to hypertension or obesity do not focus on identifying 
individuals carrying biological markers; rather they encourage 
members of the general population to take exercise and reduce their 
calory intake. A similar public health approach should be adopted to 
psychosis. Clearly, reducing urbanicity or migration is not within the 
powers of psychiatrists and minimizing childhood adversity is difficult, 
though not impossible. However, attempting to influence society’s 
consumption of high-potency cannabis is an obvious approach. 
Estimates of the proportion of cases of first onset of psychosis which 
could be prevented if no one smoked cannabis have ranged from 8% to 
24% in different countries.84 Unfortunately, public policy in the USA 
seems to be headed in the other direction with legalisation being 
accompanied by increases in the consumption and potency of 
cannabis.85 Is the USA sleep-walking toward higher rates of psychosis?  
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